TITLE:
Safety of Landiolol Infusion in Patients Undergoing Lung Resection
AUTHORS:
Kenji Ito, Masahisa Nozaki, Reinii Sakamoto, Toshiyasu Suzuki, Ryota Masuda, Masayuki Iwazaki
KEYWORDS:
Landiolol, Postoperative Arrhythmia, Lung Resection
JOURNAL NAME:
Open Journal of Anesthesiology,
Vol.4 No.8,
August
8,
2014
ABSTRACT: The efficacy of landiolol hydrochloride, an ultrashort-acting b-blocker with high b1 selectivity, has been
confirmed in patients undergoing cardiac surgery in Japan, but there have been
few reports about its use for patients having lung resection. We investigated the safety of continuous infusion of
landiolol in patients undergoing lung resection. Between May 2008 and May 2011,
200 patients scheduled for lung resection
were enrolled. Patients who underwent surgery before the introduction of
landiolol in February 2010 were studied retrospectively (Group C) and were
compared with those who received landiolol along with surgery (Group L). During
the 48-hour study period, the incidence of arrhythmias, changes in heart rate
and blood pressure, and occurrence of adverse reactions were examined. The white
blood cell count and C-reactive protein level were measured before and after
surgery to assess the anti-inflammatory effect. The heart rate was
significantly lower in Group L throughout the study period. No patient in Group
L developed hypotension requiring discontinuation of landiolol therapy, and
no respiratory symptoms (including asthma or hypoxemia) were observed. White
blood cell and C-reactive protein were significantly increased after surgery in
both groups, and there were no between-group differences. Arrhythmic events occurred
in 1.1% (1/99) and 9.2% (7/76) of Group L and Group C, respectively. One
patient in Group C developed ventricular tachycardia. Landiolol can be
administered safely during the perioperative period in patients undergoing lung
resection.